Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Other Working Capital Changes (2016 - 2025)

Lexaria Bioscience's Other Working Capital Changes history spans 10 years, with the latest figure at $22795.0 for Q3 2025.

  • For Q3 2025, Other Working Capital Changes fell 86.76% year-over-year to $22795.0; the TTM value through Nov 2025 reached $1.0, down 99.99%, while the annual FY2025 figure was $47001.0, 847.22% up from the prior year.
  • Other Working Capital Changes for Q3 2025 was $22795.0 at Lexaria Bioscience, down from $309674.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $573589.0 in Q1 2023 and bottomed at -$419453.0 in Q3 2022.
  • The 5-year median for Other Working Capital Changes is -$4963.0 (2024), against an average of -$9153.6.
  • The largest annual shift saw Other Working Capital Changes soared 599.24% in 2023 before it crashed 3809.34% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$82030.0 in 2021, then tumbled by 285.74% to -$316419.0 in 2022, then soared by 97.17% to -$8963.0 in 2023, then skyrocketed by 44.63% to -$4963.0 in 2024, then skyrocketed by 559.3% to $22795.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Other Working Capital Changes are $22795.0 (Q3 2025), $309674.0 (Q2 2025), and -$332468.0 (Q1 2025).